AlgenScribe
French tech company | Builders Republic
About
Genome-editing biotech whose platform pairs an amplified donor-DNA module with an enzyme that drives homology-directed repair — lifting recombination efficiency where nuclease-only approaches fall short, for gene therapy, oncology, bioproduction, molecular diagnostics and cell engineering.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2022
- City
- NICE
- Region
- Provence-Alpes-Côte d’Azur
- Tracked rounds
- 1
- Amount raised
- 0.5 M€ raised since 2020
Funding rounds
- Seed · 2025